ANTIDIABETIC, HYPOLIPIDEMIC AND ANTIOXIDANT ACTIVITIES AND PROTECTIVE EFFECTS OF PUNICA GRANATUM PEELS POWDER AGAINST PANCREATIC AND HEPATIC TISSUES INJURIES IN STREPTOZOTOCIN INDUCED IDDM IN RATS
Objective: There is a growing interest in traditional medicinal plants since they contain medicinally active products to remedy many diseases. Punica granatum (PG) has many medicinal applications. The aim of this study was to investigate the antidiabetic, hypolipidemic, antioxidant and hepato-pancreatic protective effects of PG peel powder (PGPP) on streptozotocin (STZ) induced diabetic rats.
Methods: Male Swiss albino rats became diabetic with insulin-dependent diabetes mellitus (IDDM) after a single intravenous injection of STZ (50 mg/kg). IDDM-rats received either a daily oral dose of PGPP (200 mg/kg), or insulin for 20 days. On day 21, rats were sacrificed and levels of fasting blood glucose (FBG), aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin, lipid profile, lipid peroxidation (LPO), nitric oxide (NO), superoxide dismutase (SOD), and total antioxidant capacity (TAC) were estimated. Histopathological studies of liver and pancreas were performed.
Results: There was a significant elevation in FBG, AST, ALT activities, NO and LPO levels for induced IDDM. In contrast, albumin level, SOD activity, and TAC exhibited the significant decline. In addition, there was marked lipid profile disturbances, and histopathological changes of liver and pancreas. Following PGPP supplementation, the levels of all the above-mentioned factors were back to normal. Also, liver architecture and the size of an islets of Langerhans of the pancreas were almost back to normal. The effect of PGPP was more pronounced when compared with insulin.
Conclusion: PGPP is an effective alternative for the treatment of IDDM through the regeneration of Î² cells of pancreas and via its strong antioxidant properties.
2. Shaikh H, Shrivastava VK. Effects of steptozotocin induced diabetes mellitus type 1 on the rat brain antioxidant status and activity of acetyl-cholinesterase: a novel and potential treatment by Vitex negundo. Int J Pharm Pharm Sci 2014;6(10):252-6.
3. Ganda OP, Rossi AA, Like AA. Studies on streptozotocin diabetes. Diabetes 1976;25:595-603.
4. Holman RR, Turner RC. Oral agent and insulin in the treatment of NIDDM. In: Pickup J, Williams G, ed. Textbook of diabetes. Oxford: Blackwell Publication; 1991. p, 467-9.
5. Elfalleh W, Nasri N, Marzougui N, Thabti I, M'rabet A, Yahya Y, et al. Physico-chemical properties and DPPH-ABTS scavenging activity of some local pomegranate (Punica granatum) ecotypes. IJFANS 2009;60(S2):197-210.
6. Jurenka JS. Therapeutic applications of pomegranate (Punica granatum L.): a review. Altern Med Rev 2000;13(2):128-44.
7. Nozire O, Serpil D. Valuation of the pomegranate (Punica granatumL.) peels from the stand point of pharmacy. Ankara Eczb Fak Derg 1993;22(1-2):21.
8. Ozcan MM, Dursun N, SaÄŸlam C. Heavy metals bounding ability of pomegranate (Punica granatum) peel in model system. Int J Food Prop 2011;14(3):550-6.
9. Ardekani MRS, Hajimahmoodi M, Oveisi MR, Sadegh N, Jannat B, Ranjbar AM, et al. Comparative antioxidant activity and total flavonoid content of persian pomegranate (Punica granatum L.) cultivars. Iran J Pharm Res 2011;10(3):519â€“24.
10. Bhowmik D, Gopinath H, Kumar BP, Duraivel S, Aravind G, Kumar SKP. Medicinal uses of Punica granatum and Its health benefits. J Pharmacogn Phytochem 2013;1(5):28-35.
11. Khalil EAM. Antidiabetic effect of an aqueous extract of Pomegranate (Punica granatum L.) peels in normal and alloxan diabetic rats. EJHM 2004;16:92â€“9.
12. Ahmed AT, Belal SK, Salem AGE. Protective effect of pomegranate peel extract against diabetic-induced renal histo-pathological changes in albino rats.â€ IOSR-JDMS 2014;13(10):94-105.
13. NIH [National Institutes of Health]. Guide for the care and use of laboratory animals. 7th ed. Washington, DC: National Academy Press; 1996.
14. Harris DC. QuantitatiÎ½e Chemical Analysis. 4th ed. New York: WH Freeman, Company; 1995.
15. Hiller WF1, Vogt P, Steiniger B, Klempnauer J, Vogf P, Steiniger B, et al. Combined transplantation of islets and kidney: Immunogenetic analysis in the rat. Transplant Proc 1993;25(1-2):976-7.
16. Sassy-Prigent C, Heudes D, Mandet C, Belair MF, Michel O, Perdereau B, et al. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 2000;49:466-75.
17. Moghaddam G, Sharifzadeh M, Hassanzadeh G, Khanavi M, Hajimahmoodi M. Anti-Ulcerogenic activity of the pomegranate peel (Punica granatum) methanol Extract. FNS 2013;4:43-8.
18. Nogueira DG, Pereira NA. Effect of an alcoholic extract from the pericarp of roma (Punica grantum L.) on insulin hypoglycaemia mice. Rev Bras Farm 1986;67:59.
19. Zafar R, Singh J. Antidiabetic activity of Punica granatum Linn. Sci Culture 1990;56(7):3.
20. Banihani S, Swedan S, Alguraan Z. Pomegranate and type 2 diabetes. Nutr Res 2013;33(5):341-8.
21. Medjakovic S, Jungbauer A. Pomegranate: a fruit that ameliorates metabolic syndrome. Food Funct 2013;4(1):19-39.
22. Habib SA, Saad EA, Elsharkawy AA, Attia ZR. Pro-inflammatory adipocytokines, oxidative stress, insulin, Zn and Cu: Interrelations with obesity in Egyptian non-diabetic obese children and adolescents. Adv Med Sci 2015;60(2):179-85.
23. Abou-seif MA, Youssef A. Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta 2004;346:161-70.
24. Kedziora-Kornatowska KZ, Luciak M. Lipid peroxidation and activities of antioxidant enzymes in the diabetic kidney: effect of treatment with angiotensin convertase inhibitors. IUBMB Life 2000;49:303â€“7.
25. Astaneie F, Afshari M, Mojtahedi A, Mostafalou S, Zamani MJ, Larijani B, et al. Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent diabetic patients. Arch Med Res 2005;36(4):376â€“81.
26. Willems D, Dorchy H, Dufrasne D. Serum antioxidant status and oxidized LDL in well-controlled young type 1 diabetic patients with and without subclinical complications. Atheroscler 1998;137:61â€“4.
27. Penckofer S, Schwertz D, Florczak K. Oxidative stress and cardiovascular disease in type 2 diabetes: the role of antioxidants and prooxidants. J Cardiovascular Nursing 2002;16(2):68â€“85.
28. Abdel-Wahab MH, Abd-Allah AR. Possible protective effect of melatonin and/or desferrioxamine against streptozotocin-induced hyperglycemia in mice. Pharmacol Res 2000;41(5):533-7.
30. Saad MF, Greco S, Osei K, Lewin AJ, Edwards C, Nunez M, et al. Ragaglitazar improves glycemic control and lipid profile in type II diabetic subjects: A 12-week double-blind placebo-controlled doseranging study with an open pioglitazone arm. Diabetes Care 2004;27:1324-9.
31. Yanadag R, Ozsoy-Sacan O, Bolkent S, Orak H, Karabulut-Bulan O. Protective effects of metoformin treatment on the liver injury of streptozotocin-diabetic rats. Hum Exp Toxicol 2005;24(3):129-35.
32. Ene A, Nwanko E, Samdi L. Alloxan-induced diabetes in rats and effects of black caraway (Carum carvi L.) oil on their body weight. Res J Medic Med Sci 2007;2(2):48-52.
33. Jasmine R, Daisy P. Hypoglycemic and hypolipidemic activity of eugenia jambolana in streptozotocin-diabetic rats. Asian J Biochem 2007;2(4):269-73.
34. Toklu HZ, Dumlu MU, Sehirli O, Ercan F, Gedik N, GÃ¶kmen V, et al. Pomegranate peel extract prevents liver fibrosis in biliary-obstructed rats. J Pharm Pharmacol 2007;59(9):1287-95.